TargeTrust Biotech.

Universal Early Stage Cancer Screening and Universal Cancer-Specific Drug Development 

 # Vision and Mission:

     We universal cancer-specific drugs. Our products can greatly reduce the global cancer problem. The world’s only methods for: 

1. Producing universal cancer-specific drugs and high-resolution tumor imaging agents.

2. Universal early stage cancer screening to cut tumors away, making cancer cured easily.

3. Real-time therapy resistance detection. Guiding correct therapy. Preventing patients from taking ineffective drugs.

4. Guiding precision dosing. Reducing drug side-effects in cancer therapy.

5. Detecting early cancer relapse to timely treat it.

6. Real-time cancer action detection.

# Problems in Caner Treatment:

1. Most cancers are detected too late by current methods, making cancer hard to treat.

2. Therapy resistance:30～70% treating drugs become ineffective; patients take ineffective drugs; delay therapy; hightly lethal.

3. Drug side-effects: Patients uncomfortable; may disrupt therapy; cause other diseseases; sometime lethal.

4. Current methods (CT, MRI, PET, CTC & ctDNA liquid biopsies, traditional biomarkers, CancerSEEK, Grail MCED Test) assay cancer and cancer therapy response at cancer progression stage (increased tumor size, tumor invade other organs), these take many months, too late, delaying therapy. The sensitivities of current methods in detecting early stage cancer are low.

 # Our Invention-1:  

     Tumor signal transductions stimulate cancer development. Tumor signal transductions take less than 1 hour and sustained. We create a novel medical field "Tumor Signal Transduction-Liquid Biopsy" to assay tumor signal transduction in blood. It is the world's only method to detect cancer development, therapy resistance, and precision dosing, in real time. 

# Our Invention-2:   

    Universal cancer-specific drugs are effective to all patients and can completely kill all tumors in the bodies of patients, increasing therapy efficacy, decreasing therapy resistance and cancer relapse.  We invent a method to produce universal cancer-specific drugs.

       Our inventions lead the future of cancer care, opening up a huge new pharmaceutical industry.

Invention-1: Tumor Signal Transduction-Liquid Biopsy

Clinical Trials

Competitive Analysis

Invention-2:  Universal Cancer-Specific Biomarker    

         We invent a method to produce universal cancer-specific drugs.

 p-CSE1L:

(1)  It is significantly expressed in most cancer types, essential for cancer cell survival & proliferation.

(2)  It accumulates in tumor vesicle membrane.

(3)  Tumors have oncogenes which result in CSE1L phosphorylation and high tumor p-CSE1L.  

Normal tissues  don’t express oncogene, p-CSE1L is undetectable

(4)  CSE1L-imaging agent can target tumor. 

Utility: Produce universal cancer-specific drugs and imaging agents

1. Targeted contrast agent for image-guided precision cancer surgery.

2. Targeted imaging agent for precision radiotherapy.

3. Targeted antibody-contrast agent for MRI high-resolution tumor imaging to detect currently undetectable occult small metastases.

4. Targeted antibody-contrast agent for PET high-resolution tumor imaging to detect currently undetectable occult small metastases.

5. Antibody-drug conjugates (ADC), antibody radiodrug conjugate (ARC), and peptide-drug conjugates.

6. Bispecific antibody for cancer immunotherapy.

7. Targeted liposome drugs.

8. Nanoparticles for targeted magnetic hyperthermia therapy.

9. Cancer vaccine. 

Advantages of Universal Cancer-Specific Drugs

1.  All tumors have the biomarker, thus, universal cancer-specific drugs are effective to all patients.  Comparatively, current drugs are only effective to a part of patient.

2. Universal cancer-specific drugs can completely kill all tumors in the bodies of patients, increasing therapy efficacy, decreasing therapy resistance and cancer relapse. Comparatively, due to tumor heterogeneity, current drugs often only kill a portion of tumors, therapy resistance and cancer relapse occur frequently.

3. Specific killing tumor cells, minimizing normal cell damage, decreasing drug side-effects-caused other diseases, lifespan shorten, and secondary cancers.

4. Simplify cancer therapy, no need to analyze the complex tumor genetic mutation profile to select a matching traditional drug for a patient.

5. Reduce the timelines, costs, and improve drug accessibility in comparison with that of the high attrition rates of new drug candidates in developing traditional drugs.

6. Simplify drug development; no need to develop each drug to each cancer type on by one, reducing the works and costs of drug development and drug price.

7. By developing drugs based on existing known universal cancer-specific biomarkers rather than starting from invoking accidental luck to screen new traditional drugs, pharmaceutical companies can lower the finance and barriers of drug development and drug price.

Patents

Contact: jiangmwd@gmail.com